These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 24980672)

  • 1. Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.
    De Ciuceis C; Savoia C; Arrabito E; Porteri E; Mazza M; Rossini C; Duse S; Semeraro F; Agabiti Rosei C; Alonzo A; Sada L; La Boria E; Sarkar A; Petroboni B; Mercantini P; Volpe M; Rizzoni D; Agabiti Rosei E
    Hypertension; 2014 Oct; 64(4):717-24. PubMed ID: 24980672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
    Rizzoni D; Porteri E; De Ciuceis C; Sleiman I; Rodella L; Rezzani R; Paiardi S; Bianchi R; Ruggeri G; Boari GE; Muiesan ML; Salvetti M; Zani F; Miclini M; Rosei EA
    Hypertension; 2005 Apr; 45(4):659-65. PubMed ID: 15723969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.
    Fogari R; Mugellini A; Zoppi A; Preti P; Maffioli P; Perrone T; Derosa G
    Expert Opin Pharmacother; 2013 Mar; 14(4):371-84. PubMed ID: 23414196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliskiren versus ramipril in hypertension.
    Verdecchia P; Angeli F; Mazzotta G; Martire P; Garofoli M; Gentile G; Reboldi G
    Ther Adv Cardiovasc Dis; 2010 Jun; 4(3):193-200. PubMed ID: 20418269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.
    Makówka A; Olejniczak-Fortak M; Nowicki M
    Kidney Blood Press Res; 2012; 36(1):18-25. PubMed ID: 22777192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients.
    Savoia C; De Ciuceis C; Paini A; Carletti R; Arrabito E; Nicoletti C; Mercantini P; Di Gioia C; Battistoni A; Ucci S; Filippini A; Agabiti Rosei E; Volpe M; Muiesan ML; Rizzoni D; Salvetti M
    J Hypertens; 2021 Jan; 39(1):169-180. PubMed ID: 32740409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension.
    Guo JQ; Wang HY; Sun NL
    Chin Med J (Engl); 2013 Apr; 126(7):1242-6. PubMed ID: 23557551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
    Zhu JR; Sun NL; Yang K; Hu J; Xu G; Hong H; Wang R; Tu YM; Ritter S; Keefe D;
    Hypertens Res; 2012 Jan; 35(1):28-33. PubMed ID: 21900941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.
    Imbalzano E; Scarpelli M; Mandraffino G; Creazzo M; Lizio G; Trapani G; Dattilo G; Dalbeni A; Tomasello C; Sardo MA; Saitta A
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):956-64. PubMed ID: 25070350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients.
    Virdis A; Ghiadoni L; Qasem AA; Lorenzini G; Duranti E; Cartoni G; Bruno RM; Bernini G; Taddei S
    Eur Heart J; 2012 Jun; 33(12):1530-8. PubMed ID: 22450428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.
    Duprez DA; Munger MA; Botha J; Keefe DL; Charney AN
    J Hum Hypertens; 2010 Sep; 24(9):600-8. PubMed ID: 20033075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS.
    Baschiera F; Chang W; Brunel P;
    Vasc Health Risk Manag; 2014; 10():389-97. PubMed ID: 25061313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes.
    Savoia C; Arrabito E; Parente R; Sada L; Madaro L; Nicoletti C; Zezza L; Alonzo A; Rubattu S; Michelini S; Muller DN; Volpe M
    Clin Sci (Lond); 2013 Aug; 125(4):183-9. PubMed ID: 23438195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment.
    Endemann DH; Pu Q; De Ciuceis C; Savoia C; Virdis A; Neves MF; Touyz RM; Schiffrin EL
    Hypertension; 2004 Feb; 43(2):399-404. PubMed ID: 14707158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of aliskiren on vascular remodelling in small retinal circulation.
    Jumar A; Ott C; Kistner I; Friedrich S; Schmidt S; Harazny JM; Schmieder RE
    J Hypertens; 2015 Dec; 33(12):2491-9. PubMed ID: 26398851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.